Amazing number of trials for Alzheimer's in NYS,
Post# of 1460
Posted On: 12/05/2015 9:28:36 PM
Amazing number of trials for Alzheimer's in NYS,
Fletch
https://www.nia.nih.gov/alzheimers/clinical-t...y=New-York
Your Search for state of New-York Identified 33 Trial(s):
1. ABT-957 in Subjects with Mild to Moderate Alzheimer's Taking Acetylcholinesterase Inhibitors
Purpose: To evaluate the safety, tolerability, and pharmacokinetics of ABT-957 in people with mild to moderate Alzheimer's disease.
2. AC-1204 for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.
3. Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Purpose: To build a clinical research consortium to test new treatments for people with frontotemporal lobar degeneration.
4. Aerobic & Cognitive Exercise Study (ACES)
Purpose: To clarify the benefits to brain health and thinking processes that result from different forms of exercise.
5. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)
Purpose: To test whether an anti-amyloid investigational drug, solanezumab, can slow memory and cognitive decline in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia.
6. AZD0530 in Mild Alzheimer's Disease (Connect Study)
Purpose: To determine the safety and efficacy of the experimental drug AZD0530 in older adults with mild Alzheimer's disease.
7. AZD3293 in Early Alzheimer's Disease (AMARANTH)
Purpose: To assess the efficacy and safety of AZD3293 as a possible treatment for early Alzheimer´s disease.
8. BAN2401 for Early Alzheimer's Disease
Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.
9. Benfotiamine in Alzheimer's Disease
Purpose: To determine whether treatment with benfotiamine, a dietary supplement, minimizes cognitive decline in older adults with amnestic mild cognitive impairment or mild Alzheimer's disease.
10. BI 409306 for Cognitive Impairment Due to Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with cognitive impairment due to Alzheimer's disease.
11. BI 409306 for Early-Stage Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with early Alzheimers disease.
12. Crenezumab for Mild to Moderate Alzheimer Disease
Purpose: To evaluate the safety and tolerability of crenezumab in older adults with mild to moderate Alzheimer's disease.
13. Dominantly Inherited Alzheimer Network (DIAN)
Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
14. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU)
Purpose: To assess the safety, tolerability, and biomarker efficacy of gantenerumab and solanezumab in individuals who have a genetic mutation for autosomal-dominant Alzheimer's disease.
15. EMERGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).
16. ENGAGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).
17. Gantenerumab for Mild Alzheimer Disease
Purpose: To evaluate the efficacy and safety of the experimental drug gantenerumab as a possible treatment for people with mild Alzheimer disease.
18. Hispanic Caregiver Intervention Effectiveness Study
Purpose: To compare two dementia caregiver interventions to determine which is most effective for Hispanic caregivers in New York City.
19. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders
Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.
20. Imaging of Cognition, Learning, and Memory in Aging
Purpose: To study how the brain functions when it performs explicit memory tasks and how this changes as a function of aging.
21. Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)
Purpose: To learn about thinking and behavior in families in which one or more relatives has a genetic mutation associated with frontotemporal dementia.
22. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.
23. MK-7622 in People with Alzheimer's Disease Taking Donepezil
Purpose: To test the efficacy and safety of MK-7622 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.
24. MK-8931 for Amnestic Mild Cognitive Impairment (APECS)
Purpose: To assess MK-8931 as a possible treatment for amnestic mild cognitive impairment due to Alzheimer's disease.
25. NOBLE: T-817MA for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the efficacy of the experimental drug T-817MA as a potential treatment for people with mild to moderate Alzheimer's disease.
26. Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Older Adults
Purpose: To determine if a worsened sense of smell can identify older people who might benefit from treatment with the Alzheimer's drug donepezil.
27. PET Imaging with 18F-AV-1451
Purpose: To evaluate the characteristics of the brain imaging agent 18F-AV-1451 in cognitively healthy volunteers and in people with mild cognitive impairment or Alzheimer's disease.
28. Prediction of Mild Cognitive Impairment and Pioglitazone to Delay Its Onset (TOMMORROW)
Purpose: To develop a biomarker that predicts the risk of mild cognitive impairment due to Alzheimer's disease and to test the drug pioglitazone to delay the onset of MCI.
29. Riluzole for Mild Alzheimer's Disease
Purpose: To test the safety and effectiveness of the drug riluzole for treating mild Alzheimer's disease.
30. Sleep-Disordered Breathing and Alzheimer's Disease Prevention (SNAP)
Purpose: To examine the relationship between sleep-disordered breathing and Alzheimer's disease in cognitive normal older adults.
31. STARBEAM: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test Lu AE58054 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.
32. STARSHINE: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test the drug Lu AE58054 as an add-on therapy to donepezil for people with mild to moderate Alzheimer's disease.
33. Treatment of Psychosis and Agitation in Alzheimer's Disease
Purpose: To test lithium as a treatment for psychosis and agitation in older adults with Alzheimer's disease.
Return to AD Clinical Trials Search Results
Return to AD Clinical Trials Home
Fletch
https://www.nia.nih.gov/alzheimers/clinical-t...y=New-York
Your Search for state of New-York Identified 33 Trial(s):
1. ABT-957 in Subjects with Mild to Moderate Alzheimer's Taking Acetylcholinesterase Inhibitors
Purpose: To evaluate the safety, tolerability, and pharmacokinetics of ABT-957 in people with mild to moderate Alzheimer's disease.
2. AC-1204 for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.
3. Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Purpose: To build a clinical research consortium to test new treatments for people with frontotemporal lobar degeneration.
4. Aerobic & Cognitive Exercise Study (ACES)
Purpose: To clarify the benefits to brain health and thinking processes that result from different forms of exercise.
5. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)
Purpose: To test whether an anti-amyloid investigational drug, solanezumab, can slow memory and cognitive decline in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia.
6. AZD0530 in Mild Alzheimer's Disease (Connect Study)
Purpose: To determine the safety and efficacy of the experimental drug AZD0530 in older adults with mild Alzheimer's disease.
7. AZD3293 in Early Alzheimer's Disease (AMARANTH)
Purpose: To assess the efficacy and safety of AZD3293 as a possible treatment for early Alzheimer´s disease.
8. BAN2401 for Early Alzheimer's Disease
Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.
9. Benfotiamine in Alzheimer's Disease
Purpose: To determine whether treatment with benfotiamine, a dietary supplement, minimizes cognitive decline in older adults with amnestic mild cognitive impairment or mild Alzheimer's disease.
10. BI 409306 for Cognitive Impairment Due to Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with cognitive impairment due to Alzheimer's disease.
11. BI 409306 for Early-Stage Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with early Alzheimers disease.
12. Crenezumab for Mild to Moderate Alzheimer Disease
Purpose: To evaluate the safety and tolerability of crenezumab in older adults with mild to moderate Alzheimer's disease.
13. Dominantly Inherited Alzheimer Network (DIAN)
Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
14. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU)
Purpose: To assess the safety, tolerability, and biomarker efficacy of gantenerumab and solanezumab in individuals who have a genetic mutation for autosomal-dominant Alzheimer's disease.
15. EMERGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).
16. ENGAGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).
17. Gantenerumab for Mild Alzheimer Disease
Purpose: To evaluate the efficacy and safety of the experimental drug gantenerumab as a possible treatment for people with mild Alzheimer disease.
18. Hispanic Caregiver Intervention Effectiveness Study
Purpose: To compare two dementia caregiver interventions to determine which is most effective for Hispanic caregivers in New York City.
19. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders
Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.
20. Imaging of Cognition, Learning, and Memory in Aging
Purpose: To study how the brain functions when it performs explicit memory tasks and how this changes as a function of aging.
21. Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)
Purpose: To learn about thinking and behavior in families in which one or more relatives has a genetic mutation associated with frontotemporal dementia.
22. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.
23. MK-7622 in People with Alzheimer's Disease Taking Donepezil
Purpose: To test the efficacy and safety of MK-7622 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.
24. MK-8931 for Amnestic Mild Cognitive Impairment (APECS)
Purpose: To assess MK-8931 as a possible treatment for amnestic mild cognitive impairment due to Alzheimer's disease.
25. NOBLE: T-817MA for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the efficacy of the experimental drug T-817MA as a potential treatment for people with mild to moderate Alzheimer's disease.
26. Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Older Adults
Purpose: To determine if a worsened sense of smell can identify older people who might benefit from treatment with the Alzheimer's drug donepezil.
27. PET Imaging with 18F-AV-1451
Purpose: To evaluate the characteristics of the brain imaging agent 18F-AV-1451 in cognitively healthy volunteers and in people with mild cognitive impairment or Alzheimer's disease.
28. Prediction of Mild Cognitive Impairment and Pioglitazone to Delay Its Onset (TOMMORROW)
Purpose: To develop a biomarker that predicts the risk of mild cognitive impairment due to Alzheimer's disease and to test the drug pioglitazone to delay the onset of MCI.
29. Riluzole for Mild Alzheimer's Disease
Purpose: To test the safety and effectiveness of the drug riluzole for treating mild Alzheimer's disease.
30. Sleep-Disordered Breathing and Alzheimer's Disease Prevention (SNAP)
Purpose: To examine the relationship between sleep-disordered breathing and Alzheimer's disease in cognitive normal older adults.
31. STARBEAM: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test Lu AE58054 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.
32. STARSHINE: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test the drug Lu AE58054 as an add-on therapy to donepezil for people with mild to moderate Alzheimer's disease.
33. Treatment of Psychosis and Agitation in Alzheimer's Disease
Purpose: To test lithium as a treatment for psychosis and agitation in older adults with Alzheimer's disease.
Return to AD Clinical Trials Search Results
Return to AD Clinical Trials Home
(0)
(0)Anavex Life Sciences Corp. (AVXL) Stock Research Links
Scroll down for more posts ▼